Trial Radar AI | ||
|---|---|---|
Clinical Trial NCT07491653 (GO-FAR) for Prediabetes is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here. | ||
One study matched filter criteria
Card View
Fiber mHealth Intervention for Prediabetes (GO-FAR) 80
Clinical Trial NCT07491653 (GO-FAR) is an interventional study for Prediabetes that is recruiting. It started on 31 March 2026 with plans to enroll 80 participants. Led by University of Oklahoma, it is expected to complete by 1 July 2028. The latest data from ClinicalTrials.gov was last updated on 24 March 2026.
Brief Summary
This is a single-arm feasibility trial to examine an mHealth intervention that combines high fiber education, home-delivered high fiber foods, and use of continuous glucose monitors.
Detailed Description
This is a single-arm trial enrolling young adults (aged 18-39) with prediabetes (based on hemoglobin A1c). Enrolled individuals will complete baseline data collection in person to assess insulin resistance (venous blood samples). Enrolled individuals will then complete a three-month fully-mHealth based intervention focused exclusively on helping them eat more fiber. They will receive weekly home-delivered shipments o...Show More
Official Title
Preliminary Examination of an Innovative mHealth-Based Dietary Fiber Intervention to Improve Outcomes in Young Adults With Prediabetes: A Feasibility Study
Conditions
PrediabetesOther Study IDs
- GO-FAR
- 18705
NCT ID Number
Start Date (Actual)
2026-03-31
Last Update Posted
2026-03-24
Completion Date (Estimated)
2028-07-01
Enrollment (Estimated)
80
Study Type
Interventional
PHASE
N/A
Status
Recruiting
Keywords
Diet
Young adults
Fiber
Diabetes
Young adults
Fiber
Diabetes
Primary Purpose
Prevention
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
| Participant Group/Arm | Intervention/Treatment |
|---|---|
ExperimentalFiber-focused intervention Mobile phone delivered content about fiber (daily), continuous glucose monitors, and home delivered high fiber foods | GO-FAR 3-month intervention combining multiple behavior change techniques (biofeedback, adding objects to the environment, instruction on how to perform the behavior), all focused on helping people at more fiber. |
Primary Outcome Measures
Secondary Outcome Measures
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Recruitment (as a measure of intervention feasibility) | We will assess what percent of our recruitment goal was reached. | Evaluated at the end of the project period (2 years in total) |
Retention of participants (as a measure of feasibility) | We will measure the percent of enrolled participants who remain in the study throughout the intervention period | Retention will be based on time retained in the study over a period of approximately 5 months (from enrollment to completion of follow-up data collection) |
Acceptability (as a measure of feasibility) | Participants will rate their perceived acceptability of the intervention using a 5-point Likert scale question ("How would you rate this study intervention as a whole?" rated as Poor, Fair, Good, Very Good, Excellent. | Measured at the end of the 3-month intervention |
| Outcome Measure | Measure Description | Time Frame |
|---|---|---|
Dietary fiber intake | Measured using the automated self-administered 24-hour recall | Baseline, after-intervention (3-months), and after a 4-week observation period |
Glycemic control (hemoglobin A1c [HbA1c]) | Measured via point-of-care testing devices | Baseline and after the intervention (3 months) |
Insulin resistance (Homeostatic Model Assessment of Insulin Resistance [HOMA-IR]) | Measured via venous blood samples | Baseline and after-intervention (3 months) |
Participation Assistant
Eligibility Criteria
Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
- Pre-diabetes based on HbA1c
- Young adult, aged 18-39 years
- Reside near Tulsa metro area
- Ability to access/use a compatible smartphone
- Proficient in English
- Suspected eating disorder
- Current glucagon-like peptide-1 receptor agonist use
- Food allergies or intolerances
- Currently pregnant or breastfeeding
Study Central Contact
Contact: Ashlea Braun, PhD, 918.660.3080, [email protected]
1 Study Locations in 1 Countries
Oklahoma
University of Oklahoma Health Campus, Tulsa, Oklahoma, 74135, United States
Ashlea Braun, PhD, Contact, 567-240-1582, [email protected]
Recruiting